Bayesian cost-effectiveness analysis based on the persistence with antihypertensive treatment

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 3, Issue 3, 2003, Pages 227-236

  Baio, Gianluca ^a   Degli Esposti, Luca ^b   Degli Esposti, Ezio ^d   Saragoni, Stefania ^b   Capone, Alessandro ^b   Russo, Pierluigi ^c   Pammolli, Fabio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Economics and Outcomes Research   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Faculty of Economics ^*

Author keywords

Antihypertensive treatment; Bayesian analysis; Claims databases; Cost effectiveness evaluation; Observational studies; Public health perspective

Indexed keywords

AMLODIPINE BESYLATE; ANTIHYPERTENSIVE AGENT; ATENOLOL; DIURETIC AGENT; FOSINOPRIL; INDAMOL; INDAPAMIDE; LORTAAN; LOSARTAN; TENSOGARD;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BAYES THEOREM; CLINICAL OBSERVATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; FOLLOW UP; HEALTH CARE COST; HEALTH CENTER; HUMAN; HYPERTENSION; ITALY; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PROBABILITY;

EID: 0037666220     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.3.3.227     Document Type: Article

References (28)

1. MacMahon SW, Cutler JA, Furberg CD et al. The effect of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomised clinical trials. Prog. Cardiovascular Dis. 29(Suppl. 1), 99-118 (1986).
2. SHEP CO-operative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). J. Am. Med. Assoc. 265, 3255-3264 (1991).
3. Hypertension prevalence and the status of awareness, treatment and control in the United States. Final report of the Subcommittee on Definition and Prevalence of the 1984 joint National Committee. Hypertension 7, 457-468 (1985).
4. Jones JK, Gorkun L, Lian JF et al. Discontinuation of and changes in the treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. Brit. Med. J. 311, 293-295 (1995).
5. Mancia G, Sega R, Milesi C et al. Blood pressure control in the hypertensive population. Lancet 349, 454-457 (1997).
6. Avorn J, Monette J, LeLorier J et al. Persistence of use of lipid-lowering medications: a cross-national study. J Am. Med. Assoc. 279(18), 1458-1462 (1998).
7. LeLorier J, Page V, Castilloux AM et al. The management of new symptoms of dyspepsia in Quebec elderly. Can. J. Gastroenterolgy 11(8),669-672 (1997).
8. Spitzer WO, Suissa S, Ernst P et al. The use of β-agonists and the risk of death and near death from asthma. N. Eng. J. Med. 326, 501-505 (1992).
9. Degli Esposti E, Sturani A, Degli Esposti L et al. Pharmacoutilization of antihypertensive drugs: a model of analysis. Int. J. Clin. Pharmacol. Therapeutics 6, 251-258 (2001).
10. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). The sixth report of the JNC VI. Arch. Intern. Med. 157, 2413-2446 (1997).
11. Briggs AH. A Bayesian approach to stochastic cost-effectiveness analysis. Health Econ. 8, 257-261 (1999).
12. Briggs AH. Bayesian cost-effectiveness analysis for frequentists: interpreting cost-effectiveness acceptability curves. (Work In Progress).
13. O'Hagan A, Stevens JW. A framework for cost-effectiveness analysis from clinical trial data. Health Econ. (In Press).
14. O'Hagan A, Stevens JW, Montmartin J. Bayesian cost effectiveness analysis from clinical trial data. Stat. Med. 20, 733-753 (2001).
15. Bernardo JM, Smith AFM. Bayesian Theory. John Wiley and Sons, London, UK (1997).
16. Gelman A, Carlin JB, Stern HS, Rubin D. Bayesian Data Analysis. Chapman Hall. NY, USA (1998).
17. O'Hagan A. Bayesian Inference. In: Kendall's Advanced Theory of Statistics, 2B. Arnold, London, UK (1994).
18. Lee PM. Bayesian Statistics. Arnold, London, UK (1998).
19. Gamerman D. Markov Chain Monte Carlo. Chapman Hall, NY, USA (1997).
20. Spiegelhalter D, Thomas A, Best N. WinBUGS, version 1.3. MRC Biostatistics Unit, Cambridge, UK (2000).
21. Brooks S, Gelman A. General methods for monitoring convergence of iterative simulations. J. Comp. Graph. Statistics 7, 434-455 (1998).
22. Gelman A, Rubin D. Inference from iterative simulation using multiple sequences. Statistical Science 7, 457-511 (1992).
23. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clinical Therapeutics 20, 1-11 (1998).
24. Drummond MF, O'Brien BJ, Stoddar GL, Torrance GW. Methods for the Economic Evaluation of Healthcare Programmes. Oxford University Press, London, UK (1997).
25. Johannesson M. The cost-effectiveness of hypertension treatment in Sweden. PharmacoEconomics 7(3), 242-250 (1995).
26. Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: recommendations for a call to action; a statement for healthcare professionals. Circulation 95, 1085-1090 (1997).
27. Mood AM, Graybill FA, Boes DC. Introduction to the Theory of Statistics. McGraw-Hill, NY, USA (1993).
28. Troche CJ, Tacke J, Hinzpeter B, Danner M, Lauterbach KW. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases. Eur. Heart J. 19(Suppl. C), C59-C65 (1998).